180 related articles for article (PubMed ID: 37993847)
1. TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer.
Wang Z; Zhu M; Dong R; Cao D; Li Y; Chen Z; Cai J; Zuo X
J Nanobiotechnology; 2023 Nov; 21(1):440. PubMed ID: 37993847
[TBL] [Abstract][Full Text] [Related]
2. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment.
Wang S; Zhou X; Zeng Z; Sui M; Chen L; Feng C; Huang C; Yang Q; Ji M; Hou P
J Nanobiotechnology; 2021 Oct; 19(1):302. PubMed ID: 34600560
[TBL] [Abstract][Full Text] [Related]
3. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Effects of Nanoscale CaO
Wang Y; Ju S; Zhou H; Bai Y; Zhou C; Liu J; Dong X; Zheng C
Int J Nanomedicine; 2024; 19():137-154. PubMed ID: 38196507
[TBL] [Abstract][Full Text] [Related]
5. Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.
Mudassar F; Shen H; Cook KM; Hau E
J Med Imaging Radiat Oncol; 2022 Jun; 66(4):560-574. PubMed ID: 35466515
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression.
Barnwal A; Tamang R; Sanjeev Das ; Bhattacharyya J
Br J Cancer; 2023 Oct; 129(6):1007-1021. PubMed ID: 37400678
[TBL] [Abstract][Full Text] [Related]
7. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
[TBL] [Abstract][Full Text] [Related]
8. Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma.
Deng Z; Teng YJ; Zhou Q; Ouyang ZG; Hu YX; Long HP; Hu MJ; Mei S; Lin FX; Dai XJ; Zhang BY; Feng T; Tian XF
World J Gastrointest Oncol; 2021 Nov; 13(11):1725-1740. PubMed ID: 34853646
[TBL] [Abstract][Full Text] [Related]
9. Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer.
Cao Y; Yu K; Zhang Z; Gu Y; Gu Y; Li W; Zhang W; Shen Z; Xu J; Qin J
Clin Transl Med; 2024 Feb; 14(2):e1578. PubMed ID: 38356419
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma.
Chen ZQ; Zuo XL; Cai J; Zhang Y; Han GY; Zhang L; Ding WZ; Wu JD; Wang XH
Exp Hematol Oncol; 2023 Feb; 12(1):17. PubMed ID: 36747292
[TBL] [Abstract][Full Text] [Related]
11. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
[TBL] [Abstract][Full Text] [Related]
12. Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression.
Finisguerra V; Dvorakova T; Formenti M; Van Meerbeeck P; Mignion L; Gallez B; Van den Eynde BJ
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37147018
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil extracellular traps induced by the hypoxic microenvironment in gastric cancer augment tumour growth.
Li J; Xia Y; Sun B; Zheng N; Li Y; Pang X; Yang F; Zhao X; Ji Z; Yu H; Chen F; Zhang X; Zhao B; Jin J; Yang S; Cheng Z
Cell Commun Signal; 2023 May; 21(1):86. PubMed ID: 37127629
[TBL] [Abstract][Full Text] [Related]
14. Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma.
Yan H; Jiang A; Huang Y; Zhang J; Yang W; Zhang W; Liu T
Front Immunol; 2023; 14():1265914. PubMed ID: 37876940
[TBL] [Abstract][Full Text] [Related]
15. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
16. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
[TBL] [Abstract][Full Text] [Related]
17. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
18. Rhamnazin Enhanced Anti-Tumor Efficacy of Anti-PD-1 Therapy for Lung Cancer in Mice through Inhibition of PD-L1 Expression.
Wang SS; Liu Y; Zhang XT; Yu DQ
Tohoku J Exp Med; 2023 May; 260(1):63-73. PubMed ID: 36823182
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
20. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
